The First Affiliated Hospital of Xiamen University
xmfh.com.cnTotal trials
108
Active
62
Phase 3
3
Total enrollment
24,497
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Liraglutide | — | — | — | — | — | 1 | |
| insulin glargine | — | — | — | — | — | 1 | |
| semaglutide combined with metformin | — | — | — | — | — | 1 | |
| Apatinib Mesylate | — | — | — | — | 3 | ||
| Mycophenolate Mofetil, Oral, 250 Mg | — | — | — | — | — | 1 | |
| methimazole, oral, 10mg | — | — | — | — | — | 1 | |
| Fluzoparib | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 2 | |
| Tislelizumab | — | — | — | — | — | 2 | |
| Intravenous the dose of esketamine ED95 | — | — | — | — | — | 2 | |
| Apatinib | — | — | — | — | — | 2 | |
| TACE with adebrelimab and bevacizumab | — | — | — | — | — | 1 | |
| Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine | — | — | — | — | — | 1 | |
| veneclax, chidaniline combined with azacitidine | — | — | — | — | — | 1 | |
| Adebrelimab+Albumin paclitaxel +Cisplatin | — | — | — | — | — | 1 | |
| Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections | — | — | — | — | — | 1 | |
| Recombinant Human Interleukin-2 Injections | — | — | — | — | — | 1 | |
| All-trans Retinoic Acid in combination with the KPD Regimen | — | — | — | — | — | 1 | |
| Azacitidine in combination with R-CHOP | — | — | — | — | — | 1 | |
| Axicabtagene Ciloleucel | — | — | — | — | — | 1 | |
| albumin-bound paclitaxel | — | — | — | — | — | 1 | |
| Nedaplatin | — | — | — | — | — | 1 | |
| Trilaciclib combined with Docetaxel | — | — | — | — | — | 1 | |
| CAR-T treatment | — | — | — | — | — | 1 | |
| Intravenous esketamine using Dixon's up-and-down sequential method | — | — | — | — | — | 1 | |
| Intravenous fentanyl 1 μg∙kg-1 | — | — | — | — | — | 1 | |
| Zanubrutinib combined with Obinutuzumab | — | — | — | — | — | 1 | |
| SBRT combined with Nimotuzumab followed by Tislelizumab | — | — | — | — | — | 1 | |
| Chidamide combined with Duvillisib | — | — | — | — | — | 1 | |
| Trilaciclib and Sacituzumab Tirumotecan | — | — | — | — | — | 1 | |
| Tofacitinib | — | — | — | — | — | 1 | |
| Lenalidomide combined with G-CHOP | — | — | — | — | — | 1 | |
| Determine the ED50 and ED95 of esketamine | — | — | — | — | — | 1 | |
| Intravenous remifentanil 1μg∙kg-1 | — | — | — | — | — | 1 | |
| Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen | — | — | — | — | — | 1 | |
| Paclitaxel for | — | — | — | — | — | 1 | |
| venetoclax combining chidamide and azacitidine | — | — | — | — | — | 1 | |
| Chidamide combined with Linperlisib | — | — | — | — | — | 1 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen | — | — | — | — | — | 1 | |
| Rezvilutamide | — | — | — | — | — | 1 |
18 more active programs hidden
Next readouts
- 2025-01-15
- 2025-10-08
- 2025-12-01
- 2025-12-20
- 2025-12-30
- 2025-12-31
- 2025-12-31
- 2025-12-31
- 2026-01-31
- 2026-03-01
Top conditions
- PET/CT7
- Positron-Emission Tomography6
- Follicular Lymphoma4
- Tumor4
- Acute Myeloid Leukemia3
- Trop23
- Solid Tumor3
- Prostate Cancer3
Frequently asked questions about The First Affiliated Hospital of Xiamen University
- How many clinical trials does The First Affiliated Hospital of Xiamen University have on ClinicalTrials.gov?
- The First Affiliated Hospital of Xiamen University is listed as the lead sponsor on 108 clinical trials in ClinicalTrials.gov, 62 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The First Affiliated Hospital of Xiamen University's trials are in Phase 3?
- 3 of The First Affiliated Hospital of Xiamen University's trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does The First Affiliated Hospital of Xiamen University focus on?
- The First Affiliated Hospital of Xiamen University's most-studied conditions on ClinicalTrials.gov are PET/CT, Positron-Emission Tomography, Follicular Lymphoma, Tumor, Acute Myeloid Leukemia.
- When are The First Affiliated Hospital of Xiamen University's next clinical trial readouts?
- The First Affiliated Hospital of Xiamen University has 10 upcoming primary-completion readouts tracked here; the soonest is “Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)”, expected around 2025-01-15.